The Dangers of Taking Xarelto

A few years back, the FDA issued approval for a new type of anticoagulant or blood-thinning drug. Xarelto, also called by its generic name Rivaroxaban, was approved by the Food and Drug Administration in 2011 for use of patients who have underwent knee and hip replacement surgery. The drug is intended to reduce their risk of developing a common blood clotting complication called deep vein thrombosis that is caused by these procedures. In the years following its approval, Xarelto has since been used to treat other conditions like pulmonary embolism, atrial fibrillation, and acute coronary syndrome.

Unlike older generations of anticoagulant drugs, Xarelto is particularly effective because it is able to slow down the body’s production of a protein that enables the formation of thrombin, a blood plasma enzyme that is responsible for blood clotting. This makes Xarelto a direct thrombin inhibitor—the first of its kind to be approved by the FDA.

While Xarelto has proven to be a highly effective drug for blood clotting conditions, cases of adverse and often deadly side effects have caused some reservations to its continued use. According to the website of lawyers at Williams Kherkher, there have been several cases of patients suffering from serious side effects caused by their use of Xarelto. There have been reported cases of Xarelto causing brain hemorrhaging and gastrointestinal bleeding. Xarelto has also been found to increase the risk of strokes, epidural hematomas, and heart-related illnesses. Other known side effects of Xarelto include vomiting blood, bleeding gums, blood in the stool and urine, frequent nosebleeds, and heavier periods.

Unfortunately, the public isn’t typically aware of the risks involved in taking Xarelto. This is because drug companies who manufacturer these direct thrombin inhibitor drugs often fail to disclose the dangers and side effects to their consumers. Unfortunately, millions of Americans are prescribed to take drugs without receiving sufficient information about it.